Cancer Care Engineering Colorectal Cancer
Gabriela Chiorean, M.D.
May 27, 2011
Rationale
Perform OMICs of healthy, polyps, cancer
Compare OMICs between cancer, polyps and healthy: develop new screening and risk assessment tools
Analyse changes in OMICs with treatment and correlate with response/toxicity: predictive markers
Schema IUCRO-0221CCE in CRC
SAMPLES
Blood (Serum)7 mL red top
Metabolomics, vit D
Blood (Plasma)21 mL purple top
Genomics, lipidomics, glycoproteomics
N=810
Stratification:- Healthy
(n=270)- Polyps
(n=270)- Cancer
(n=270)
stg 1/2
stg 3
stg 4 metastatic
Fresh Tissue10 mg polyp or50 mg cancer /
50 mg normal tissue
SHIP
DRY
ICE
8-hr fasting
Paraffin-Embedded TissueMSI, methylation, KRAS, BRAF, p53
Samples Collection Healthy Controls
Screening Colonoscopy – GI Clinic
Label specimensHealthy
if no polyps/tumor
Blood Questionnaires
N= 5 6/2009N=74 5/2010N=109 5/2011
Samples Collection Adenomatous Polyps
Screening Colonoscopy – GI Clinic
Label specimensPolyp
Polyps identified
Tissue procurement/Research specialist -Polyp cut in ½
-Place in tube with no preservative-Freeze at -70oC
Blood Questionnaires
N= 3 6/2009N= 65 5/2010N= 96 5/2011
Samples Collection Cancer
Surgery
Tissue:tumor, normal mucosa
Blood Questionnaires
Chemotherapy Follow-up
Every 3 months Up to 24 months
N= 8 6/2009 N= 34 5/2010N= 55 5/2011
Sample Acquisition4/2009-5/2011
Cancer total No prior chemo Prior chemo
n=55 n=26 n=29 Stage 1 n=6 n=6 0Stage 2 n=3 n=2 n=1Stage 3 n=17 n=10
n=7Stage 4 n=29 n=8 n=21